Quadrature Capital
MIST icon

Quadrature Capital’s Milestone Pharmaceuticals MIST Stock Holding History

Quadrature Capital’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.6K Sell
64,661
-84,444
-57% -$135K ﹤0.01% 1481
2026
Q1 		$177K Buy
+149,105
New +$261K ﹤0.01% 1144
2025
Q4 		– Sell
-223,470
Closed -$448K – 1514
2025
Q3 		$448K Buy
+223,470
New +$393K 0.01% 557

Other funds holding MIST

PCM
Pavaki Capital Management Pueblo, Colorado $287M AUM
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Simplify Asset Management
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Quadrature Capital's MIST Position: Q2 2026 in Review

Quadrature Capital reduced its Milestone Pharmaceuticals (MIST) stake by 57% in Q2 2026, selling an estimated $135K and leaving 64,661 shares worth $86.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1481.

Quadrature Capital first reported a position in MIST in Q3 2025 and has held it in 3 quarters since. The position peaked at $448K in Q3 2025. 78 funds tracked by Wall St. Rank hold MIST as of Q2 2026.

  • Quadrature Capital held 64,661 shares of Milestone Pharmaceuticals worth $86.6K as of Q2 2026.
  • Quadrature Capital sold 84,444 Milestone Pharmaceuticals shares in Q2 2026, an estimated $135K.
  • Milestone Pharmaceuticals made up ﹤0.01% of Quadrature Capital's portfolio in Q2 2026, its #1481 holding.
  • Quadrature Capital first reported a position in Milestone Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Quadrature Capital's Milestone Pharmaceuticals position peaked at $448K in Q3 2025.
  • 78 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.